10:47 AM EDT, 04/05/2024 (MT Newswires) -- NovoCure ( NVCR ) said Friday that preclinical studies of Tumor Treating Fields, or TTFields, therapy showed it can potentially boost the immune system's ability to fight cancer and lead to "significantly enhanced" therapeutic effects in pancreatic cancer.

The company said among the new insights from these preclinical investigations was that when used with standard chemotherapy, TTFields therapy significantly reduced tumor growth compared with the control group and led to a complete regression of tumors in several animals.

TTFields are electric fields that exert physical forces to kill cancer cells without seriously affecting healthy cells, the company said.

Another preclinical trial showed a new immunomodulatory role for TTFields by promoting in vitro pro-inflammatory polarization of macrophages, a type of white blood cell, the company said.

These studies are among the 20 presentations on TTFields that are set to be delivered at the ongoing American Association for Cancer Research (AACR) annual meeting, the company said.

Price: 14.13, Change: -0.16, Percent Change: -1.12